- NZ$3.09bn
- NZ$5.58bn
- NZ$570.98m
- 42
- 87
- 58
- 66
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.11 | ||
| PEG Ratio (f) | 5.63 | ||
| EPS Growth (f) | 2.02% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.64 | ||
| Price to Tang. Book | 0.65 | ||
| Price to Free Cashflow | 6.37 | ||
| Price to Sales | 4.99 | ||
| EV to EBITDA | 130.74 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.05% | ||
| Return on Equity | 5.9% | ||
| Operating Margin | -1.15% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NZ$m | 382.33 | 423.88 | 455.79 | 508.8 | 570.98 | 877.12 | 922.13 | 10.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -15.98 | -40.16 | +63.63 | +60.11 | -62.97 | +11.26 | +2.02 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ryman Healthcare Limited is a vertically integrated retirement-living and aged-care developer, owner and operator. The Company develops, owns and operates integrated retirement villages, rest homes, and hospitals for the elderly within New Zealand and Australia. It provides a range of retirement-living options, including independent apartments and townhouses and assisted living in serviced apartments. Its aged-care offering includes rest homes, hospitals and dementia care. The Company's assisted living offers a range of services, including scheduled transport services and outings, village management and administration, maintaining and operating the community amenities, and gardening and ground maintenance and others. Its one, two and three-bedroom apartments and townhouses offer a neutral color palette. It also offers musical entertainment, fashion shows, arts and crafts, and regular outings. It owns and operates 38 villages across New Zealand and seven in Victoria, Australia.
Directors
- David Kerr NEC
- Richard Umbers CEO
- David Michael Bennett CFO
- Cameron Holland CEX
- Cheyne Chalmers COO
- Marsha Cadman CMO
- Andrew Crerar OTH
- Rick Davies OTH
- Chris Evans OTH
- Jeremy Moore OTH
- Geoffrey Cumming NED
- Jo Appleyard NID
- Warren Bell NID
- Greg Campbell NID
- Claire Higgins NID
- Paula Jeffs NID
- Anthony Cameron Leighs NID (50)
- George Savvides NID
- Last Annual
- March 31st, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- May 8th, 1987
- Public Since
- June 25th, 1999
- No. of Shareholders
- 17,181
- No. of Employees
- 7,200
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New Zealand Stock Exchange- Shares in Issue
- 687,641,738
- Address
- 92 Russley Road,, CHRISTCHURCH, 8140
- Web
- https://www.rymanhealthcare.co.nz/
- Phone
- +64 33664069
- Contact
- Hayden Strickett
- Auditors
- Deloitte LLP
Upcoming Events for RYM
Full Year 2024 Ryman Healthcare Ltd Earnings Call
Ryman Healthcare Ltd Annual Shareholders Meeting
Similar to RYM
Arvida
New Zealand Stock Exchange
Greenfern Industries
New Zealand Stock Exchange
Oceania Healthcare
New Zealand Stock Exchange
Promisia Healthcare
New Zealand Stock Exchange
Radius Residential Care
New Zealand Stock Exchange
FAQ
What is the Ryman Healthcare share price?
As of Today at 19:18 UTC, shares in Ryman Healthcare are trading at NZ$4.50. This share price information is delayed by 15 minutes.
How has the Ryman Healthcare share price performed this year?
Shares in Ryman Healthcare last closed at NZ$4.50 and the price had moved by -16.51% over the past 365 days. In terms of relative price strength the Ryman Healthcare share price has underperformed the ASX All Ordinaries Index by -22.23% over the past year.
What are the analyst and broker recommendations for Ryman Healthcare?
The overall consensus recommendation for Ryman Healthcare is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ryman Healthcare dividend yield?
Ryman Healthcare does not currently pay a dividend.
Does Ryman Healthcare pay a dividend?
Ryman Healthcare does not currently pay a dividend.
When does Ryman Healthcare next pay dividends?
Ryman Healthcare does not currently pay a dividend.
How do I buy Ryman Healthcare shares?
To buy shares in Ryman Healthcare you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ryman Healthcare?
As of the previous close price of NZ$4.50, shares in Ryman Healthcare had a market capitalisation of NZ$3.09bn.
Where are Ryman Healthcare shares listed?
Here are the trading details for Ryman Healthcare:
- Country of listing: New Zealand
- Exchange: NZC
- Ticker Symbol: RYM
What kind of share is Ryman Healthcare?
Based on an overall assessment of its quality, value and momentum Ryman Healthcare is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ryman Healthcare share price forecast for 2024?
The analyst consensus target price for shares in Ryman Healthcare is NZ$6.88. That is 52.93% above the last closing price of NZ$4.50.
Analysts covering Ryman Healthcare currently have a consensus Earnings Per Share (EPS) forecast of NZ$0.40 for the next financial year.
What is the trend in the Ryman Healthcare share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ryman Healthcare. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -31.85%.
As of the last closing price of NZ$4.50, shares in Ryman Healthcare were trading -22.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ryman Healthcare PE Ratio?
The Ryman Healthcare PE ratio based on its reported earnings over the past 12 months is 11.11. The shares last closed at NZ$4.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ryman Healthcare?
Ryman Healthcare's management team is headed by:
- David Kerr - NEC
- Richard Umbers - CEO
- David Michael Bennett - CFO
- Cameron Holland - CEX
- Cheyne Chalmers - COO
- Marsha Cadman - CMO
- Andrew Crerar - OTH
- Rick Davies - OTH
- Chris Evans - OTH
- Jeremy Moore - OTH
- Geoffrey Cumming - NED
- Jo Appleyard - NID
- Warren Bell - NID
- Greg Campbell - NID
- Claire Higgins - NID
- Paula Jeffs - NID
- Anthony Cameron Leighs - NID
- George Savvides - NID